The Targeted Pulse: Regulatory Updates and Trial Data

This week in oncology, regulatory updates and practice-changing trial data took center stage. From FDA timeline extensions to shifting paradigms in colorectal and lung cancer management, here is a summary of the most significant clinical developments from the past week.

FDA Extends PDUFA Date for Orca-T in Hematologic Malignancies

The FDA has extended the review timeline for Orca-T, an investigational allogeneic T-cell immunotherapy intended for patients with myelodysplastic syndromes and leukemia. The new PDUFA target action date is July 6, 2026. This extension was granted to allow the agency additional time to review updated chemistry, manufacturing, and controls information. Despite the delay, Orca-T remains a highly anticipated therapeutic option in the transplant setting, aiming to reduce graft-vs-host disease while maintaining the graft-vs-infection effect.

Precision Medicine Advancement: Breakthrough Designation for Plixorafenib

The FDA has granted breakthrough therapy designation to plixorafenib (formerly BBI-355) for the treatment of patients with BRAF V600E-mutated gliomas. This decision is supported by early clinical data from the FORTE trial, which demonstrated durable responses in patients with this specific genetic driver. As primary brain tumors often lack targeted options, plixorafenib represents a potential shift toward precision-based interventions for high-grade and low-grade gliomas harboring the BRAF mutation.

The ATOMIC Trial: A New Standard in Stage III Colon Cancer?

Discussion surrounding the phase 3 ATOMIC trial has intensified this week, as experts highlight its practice-changing potential for stage III deficient mismatch repair (dMMR) colon cancer. The trial evaluated the addition of immunotherapy to standard adjuvant chemotherapy. Data suggest that this combination significantly improves outcomes, leading clinicians to reconsider the current standard of care and advocate for the integration of checkpoint inhibitors earlier in the treatment trajectory for this specific patient population.

ASTEROID Trial: Durvalumab and SBRT in Early-Stage NSCLC

New data from the ASTEROID trial suggest that the combination of durvalumab and stereotactic body radiation therapy (SBRT) provides a significant clinical benefit for patients with early-stage non–small cell lung cancer (NSCLC). The study found that the combination therapy significantly reduced the risk of tumor progression compared to radiation alone. While clinicians await more mature overall survival data, the current progression-free survival results suggest a promising new multi-modal approach for patients who are not candidates for surgery.

Looking Ahead: FDA Decisions to Watch in Q2

Sign-up is required to read this article.

As we enter the second quarter of 2026, several high-impact FDA decisions are on the horizon. Key therapies under review include datopotamab deruxtecan (Dato-DXd; Datroway) for breast and lung cancers, as well as sonrotoclax for hematologic malignancies. These upcoming rulings will likely dictate the clinical narrative for the remainder of the year.

Subscribe to The Targeted Pulse newsletter on LinkedIn—subscribers get early access to every edition!